ClinicalTrials.gg
Not yet recruitingNCT07941531Updated Nov 17, 2026

T-Cell Therapy Using CD7 Negative T-Cells Expressing CD7 CAR Expressed In Pediatric Patients With Hematological Malignancies.

A Phase 1 interventional study of Fludarabine and Cyclophosphamide in Lymphoma, AML and T-ALL, sponsored by St. Jude Children's Research Hospital. Not yet recruiting at 1 site in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by St. Jude Children's Research Hospital · Phase 1, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
Up to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Lymphoma by St. Jude Children's Research Hospital — 2 open to participants now, 5 under way, 2 of them phase 3. Lymphoma · St. Jude Children's Research Hospital.

Planned enrollment
12th of 16
32 · median 54
Started
2026
the only one that year
Phase 1
5 of 22
2 open now
Registered
22nd of 22
by date

Among the 22 studies in Lymphoma by St. Jude Children's Research Hospital, this one is the 12th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 1, and was the 22nd registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

2 of the 22 studies in Lymphoma by St. Jude Children's Research Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: Up to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Lymphoma by St. Jude Children's Research Hospital, or all of them as a file.
02

Study summary

Primary Objective:

To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD7 negative T-cells expressing CD7-CARs (CD7-CAR T cells) in pediatric patients with recurrent/refractory CD7+ hematological malignancies after lymphodepleting chemotherapy.

Secondary Objectives:

To evaluate the antileukemic activity of CD7-CAR T cells. As a phase I study, efficacy is not the primary objective of this study, but remains an important outcome to evaluate. We will determine the anti-leukemic activity of the CD7-CAR T cells in the bone marrow and in the treatment of extramedullary disease.

Read the detailed description

This is a Phase I clinical trial evaluating the safety of escalating doses of CD7 negative T cells expressing CD7-CARs in patients with high-risk hematological malignancies.

Patients will receive 3 days of lymphodepleting chemotherapy with Fludarabine and Cyclophosphamide. Following this, patients will receive a single infusion of CD7-CAR T cells (with dosing based on the number of CAR+ T cells and patient weight). There will be 3 escalating dose levels on the study and clearly defined dose escalation criteria are outlined.

03

Conditions studied

  • Lymphoma
  • AML
  • T-ALL
  • Hematologic Malignancy

Keywords

  • Hematological Malignancy
04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Procurement and T-cell production Eligibility*

*a previously frozen, autologous leukapheresis product can be used for T-cell production Recipient Inclusion

  • Age ≤21 years old
  • CD7+ AML

    • Relapsed disease: Patients developing recurrent disease after a prior complete remission (CR)
    • Refractory disease: Patients with persistent disease despite 2 cycles of induction chemotherapy.
  • Relapsed/refractory T-cell ALL/lymphoma

    • Relapsed disease: Patients developing recurrent disease after a prior complete remission (CR)
    • Refractory disease: Patients with persistent disease despite 2 cycles of induction chemotherapy.
  • Estimated of >12 weeks
  • or Lansky (age-dependent) performance score ≥50
  • Patients with a history of prior HCT must be clinically recovered from prior HCT therapy, have no evidence of active and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to apheresis
  • Patient must have an identified HCT donor
  • For females of childbearing age:

    • Not lactating with intent to breastfeed
    • Not pregnant with negative serum or urine pregnancy test within 7 days prior to enrollment
  • For patients on Arm A: Meets eligibility criteria to undergo autologous apheresis, or have a previously frozen, autologous leukapheresis product that can be used for T-cell production
  • For patients on Arm B: Have an available donor that meets donor criteria

Recipient Exclusion

  • Known primary immunodeficiency
  • Known positivity
  • Severe intercurrent bacterial, viral or fungal infection
  • History of to cornstarch or hydroxyethyl starch
  • Patients with acute promyelocytic leukemia (APL)
  • Known to protocol defined lymphodepleting chemotherapy regimens of Fludarabine/cyclophosphamide
  • AML patients who failed FDA-approved targeted treatment options (e.g., FLT3 inhibitors, IDH1/IDH2 inhibitors, NPM1/KMT2A, CD33-directed.We define therapy failure as meeting one of the following

    • contraindications to receiving targeted therapy; or
    • toxicities that necessitate stopping the targeted therapy; or
    • progressive disease

Donor eligibility criteria for Arm B of the study: Apheresis and manufacturing

  • Recipient with relapsed CD7+ disease
  • Allogeneic donor either previous transplant donor for recipient, or haplo-identical donor if previous transplant donor is not available or autologous collection is not feasible in patients that have not had a previous transplant
  • HIV negative
  • For females of child bearing age:
  • Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment AND

    o Not lactating with intent to breastfeed

  • Regarding donation eligibility, is identified as either:

    • Completed the process of donor eligibility determination as outlined in 21CFR 1271 and agency guidance; OR
    • Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271.

This will follow standard allogeneic donor criteria per FDA mandate as defined in our allogeneic transplant studies Recipient Pre-Treatment Tests Eligibility (Arm B) Inclusion

  • Identified eligible study recipient with relapsed and/or refractory CD7-positive hematological Exclusion
  • None

Treatment Eligibility (Arm A and Arm B) Inclusion

  • Age ≤21 years old
  • Detectable CD7+disease
  • Estimated life expectancy of >8 weeks
  • Karnofsky or Lansky (age-dependent) performance score ≥ 50
  • Patients with a history of prior allogeneic HCT must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned infusion
  • Patient must have an identified HCT donor
  • Adequate cardiac function defined as >40%, or shortening fraction ≥25%
  • without evidence of arrhythmia
  • Adequate renal function defined as or radioisotope 50 ml/min/1.73m2 (GFR 40 ml/min/1.73m2 if \< 2 years of age)
  • Adequate pulmonary function defined as forced vital capacity (FVC) ≥50% of predicted value; or pulse oximetry ≥92% on room air if patient is unable to perform pulmonary function testing
  • Total ≤ 3 times the for age, except in subjects with Gilbert's syndrome
  • (ALT) or aspartate aminotransferase (AST) ≤5 times the upper limit of normal for age
  • Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy
  • For females of child bearing age:
  • Not lactating with intent to breastfeed

    • Not pregnant with negative serum or urine pregnancy test within 7 days prior to enrollment
    • If sexually active, agreement to use until 3 months after T-cell infusion. Male partners should use a condom.
  • Available autologous transduced T-cells that has met GMP release criteria.

Exclusion

  • Known primary immunodeficiency
  • History of HIV infection
  • Clinically significant active infection including fungal infection with ongoing antifungal therapy, viral infection or uncontrolled viral reactivation of EBV, CMV, Adv, BK-virus, or HHV-6.
  • Receiving systemic therapy exceeding the equivalent of 0.5 mg/kg/day of methylprednisolone, in the 7 days prior to CD7-CAR T-cell infusion
  • Receiving systemic therapy in the 14 days prior to CD7-CAR T-cell infusion that in the opinion of PI will interfere with the infused product.
  • Active CNS disease
  • Known contraindication to the protocol defined lymphodepleting chemotherapy regimen of fludarabine/ cyclophosphamide
  • AML patients who failed FDA-approved targeted treatment options (e.g., FLT3 inhibitors, IDH1/IDH2 inhibitors, NPM1/KMT2A, CD33-directed agents). We define therapy failure as meeting one of the following:

    • contraindications to receiving targeted therapy; or
    • toxicities that necessitate stopping the targeted therapy; or
    • progressive disease
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Arm A

    patients will receive autologous CD7-CAR T-cells

    Drug: Fludarabine · Drug: Cyclophosphamide · Device: CliniMACS · Drug: Mesna

  • Experimental
    Arm B

    Patients will receive lymphodepleting chemotherapy (Cy/Flu), followed by an infusion of CD7-CAR T cells.

    Device: CliniMACS

Interventions

  • DrugFludarabine

    Day 4, 3, 2 at 40 mg/m2 dose. Intravenous.

  • DrugCyclophosphamide

    Day -2 at 90mg/m2 dose. Intravenous infusion.

  • DeviceCliniMACS

    CD7-CAR T-cell infusion

  • DrugMesna

    Given intravenously divided as 4 doses equal to 25% cyclophosphamide dose per dose of Mesna administered prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of CD7-CAR T cells (Arm A)

    Phase I design to determine the MTD of CD17-CAR T cells. Three (3) dose levels will be evaluated (1x106 cells/kg, 3x106cells/kg and 1x107 cells/kg).

    Time frame: up to 4 weeks after CD7CAR T-cell infusion

  2. Maximum Tolerated Dose (MTD) of CD7-CAR T cells (Arm B)

    Phase I design to determine the MTD of CD17-CAR T cells. Three (3) dose levels will be evaluated (1x106 cells/kg, 3x106cells/kg and 1x107 cells/kg).

    Time frame: up to 4 weeks after CD7CAR T-cell infusion

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2032, 72 months later.

Of 138 non-industry phase 1 interventional studies under Lymphoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 88. This study's planned 72 months is above that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2032
CompletionEst.
Dec 2034
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941531
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2032 (estimated)
Completion
Dec 2034 (estimated)
Last update
Nov 17, 2026

Study contacts

Paulina Velasquez, MD
Contact
referralinfo@stjude.org
888-226-4343
Paulina Velasquez, MD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion